Anonymous24 days ago
At least 162 deaths in the US and over 150 in the UK have been reported to drug regulators as potentially linked to GLP-1 weight-loss injections including Ozempic, Wegovy, and Mounjaro, with two recent fatalities in Northern Ireland prompting renewed scrutiny. While clinical trial meta-analyses show GLP-1 drugs reduce overall mortality by 12%, the voluntary adverse event reporting systems are flagging severe complications — particularly pancreatitis — at a pace that has forced both the MHRA and FDA to strengthen safety warnings amid the fastest pharmaceutical market expansion in decades.